- Glenmark has received the regulatory approval to commercialize the combination therapy of remogliflozin etabonate (100mg) + metformin hydrochloride (500/1000mg) as an adjunct to diet and exercise to improve glycemic control in T2D Mellitus patients in India under the brand names ‘Remo-M’ and Remozen-M’
- In Apr’2019, Glenmark has received approval of remogliflozin (100mg, bid) based on the P-III clinical study results evaluating remogliflozin vs dapagliflozin. With this approval, India became the first country to access remogliflozin with Glenmark being the first company to launch remogliflozin in India as ‘Remo’ and ‘Remozen’.
- Remogliflozin is a SGLT2 inhibitor, being studied in 26 global clinical studies and is launched in India as monothx. at a breakthrough price which is over 50% lower than the existing SGLT2 inhibitors available in India
Click here to read full press release/ article | Ref: Glenmark | Image: GMP News